ProMeris

RSS

Withdrawn

This medicine's authorisation has been withdrawn

metaflumizone
MedicineVeterinaryWithdrawn

Icelandic is available via eTranslation, the European Commission's machine translation service.

Translate to Icelandic | Important information about machine translation

  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

The marketing authorisation for ProMeris has been withdrawn at the request of the marketing authorisation holder.

български (BG) (217.29 KB - PDF)

Skoða

español (ES) (192.56 KB - PDF)

Skoða

čeština (CS) (217.67 KB - PDF)

Skoða

dansk (DA) (191.94 KB - PDF)

Skoða

Deutsch (DE) (193.36 KB - PDF)

Skoða

eesti (ET) (191.37 KB - PDF)

Skoða

ελληνικά (EL) (219.08 KB - PDF)

Skoða

français (FR) (193.21 KB - PDF)

Skoða

italiano (IT) (191.59 KB - PDF)

Skoða

latviešu (LV) (213.28 KB - PDF)

Skoða

lietuvių (LT) (214.74 KB - PDF)

Skoða

magyar (HU) (212.15 KB - PDF)

Skoða

Malti (MT) (218.75 KB - PDF)

Skoða

Nederlands (NL) (191.68 KB - PDF)

Skoða

polski (PL) (216.46 KB - PDF)

Skoða

português (PT) (192.4 KB - PDF)

Skoða

română (RO) (214.2 KB - PDF)

Skoða

slovenčina (SK) (215.86 KB - PDF)

Skoða

slovenščina (SL) (208.53 KB - PDF)

Skoða

suomi (FI) (191.92 KB - PDF)

Skoða

svenska (SV) (191.72 KB - PDF)

Skoða

Product information

български (BG) (389.52 KB - PDF)

Skoða

español (ES) (328.73 KB - PDF)

Skoða

čeština (CS) (374.1 KB - PDF)

Skoða

dansk (DA) (330.12 KB - PDF)

Skoða

Deutsch (DE) (340.98 KB - PDF)

Skoða

eesti (ET) (336.16 KB - PDF)

Skoða

ελληνικά (EL) (400.6 KB - PDF)

Skoða

français (FR) (342.69 KB - PDF)

Skoða

italiano (IT) (310.69 KB - PDF)

Skoða

latviešu (LV) (368.86 KB - PDF)

Skoða

lietuvių (LT) (376.46 KB - PDF)

Skoða

magyar (HU) (368.57 KB - PDF)

Skoða

Malti (MT) (376.05 KB - PDF)

Skoða

Nederlands (NL) (331.24 KB - PDF)

Skoða

polski (PL) (391.6 KB - PDF)

Skoða

português (PT) (331.45 KB - PDF)

Skoða

română (RO) (368.38 KB - PDF)

Skoða

slovenčina (SK) (386.11 KB - PDF)

Skoða

slovenščina (SL) (371.43 KB - PDF)

Skoða

suomi (FI) (337.57 KB - PDF)

Skoða

svenska (SV) (330.13 KB - PDF)

Skoða

Íslenska (IS) (332.3 KB - PDF)

Skoða

norsk (NO) (340.4 KB - PDF)

Skoða
Latest procedure affecting product information:IB/0012
08/07/2015

български (BG) (190.37 KB - PDF)

Skoða

español (ES) (144.19 KB - PDF)

Skoða

čeština (CS) (184.81 KB - PDF)

Skoða

dansk (DA) (144.38 KB - PDF)

Skoða

Deutsch (DE) (146.91 KB - PDF)

Skoða

eesti (ET) (144.06 KB - PDF)

Skoða

ελληνικά (EL) (186.84 KB - PDF)

Skoða

français (FR) (141.5 KB - PDF)

Skoða

italiano (IT) (144.6 KB - PDF)

Skoða

latviešu (LV) (189.21 KB - PDF)

Skoða

lietuvių (LT) (179.82 KB - PDF)

Skoða

magyar (HU) (175.56 KB - PDF)

Skoða

Malti (MT) (198.96 KB - PDF)

Skoða

Nederlands (NL) (141.54 KB - PDF)

Skoða

polski (PL) (163.63 KB - PDF)

Skoða

português (PT) (144.35 KB - PDF)

Skoða

română (RO) (142.48 KB - PDF)

Skoða

slovenčina (SK) (181.1 KB - PDF)

Skoða

slovenščina (SL) (174.66 KB - PDF)

Skoða

suomi (FI) (144.95 KB - PDF)

Skoða

svenska (SV) (141.76 KB - PDF)

Skoða

Íslenska (IS) (141.82 KB - PDF)

Skoða

norsk (NO) (141.71 KB - PDF)

Skoða

Product details

Name of medicine
ProMeris
Active substance
metaflumizone
International non-proprietary name (INN) or common name
metaflumizone
Species
Cats
Anatomical therapeutic chemical veterinary (ATCvet) code
QP53AX25

Pharmacotherapeutic group

Ectoparasiticides for topical use, incl. insecticides

Therapeutic indication

Treatment and prevention of flea infestations (Ctenocephalides canis and C. felis) in cats. The veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).

Authorisation details

EMA product number
EMEA/V/C/000107
Marketing authorisation holder
Pfizer Limited 

Pfizer Limited
Ramsgate Road
Sandwich
Kent CT13 9NJ
United Kingdom

Marketing authorisation issued
19/12/2006
Revision
8

Assessment history

This page was last updated on

Share this page